Mechanisms of trastuzumab resistance and their clinical implications.
作者： KENG-HSUEH LAN , CHIEN-HSING LU , D.HUA YU
关键词: Monoclonal 、 PI3K/AKT/mTOR pathway 、 Breast cancer 、 Cancer treatment 、 Cardiac dysfunction 、 Oncology 、 Trastuzumab 、 Trastuzumab resistance 、 Drug resistance 、 Medicine 、 Internal medicine
摘要: Trastuzumab (Herceptin) is an excellent model of rationally designed targeted cancer treatment. However, less than 35% patients with ErbB2-positive breast tumors respond to trastuzumab as a single agent, and 2-5% trastuzumab-treated suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms antitumor function cellular defects leading resistance summarized. Also explored potential combination therapies for reversing resistance.
harvard.edu
sci-hub.se 参考文章(27)
Joan Albanell, Jordi Codony, Ana Rovira, Begoña Mellado, Pere Gascón, Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4 Advances in Experimental Medicine and Biology. ,vol. 532, pp. 253- 268 ,(2003) , 10.1007/978-1-4615-0081-0_21
Steven Seelig, Carlos L. Arteaga, Walter King, F. Michael Yakes, Wichai Chinratanalab, Christoph A. Ritter, Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action Cancer Research. ,vol. 62, pp. 4132- 4141 ,(2002)
R M Hudziak, G D Lewis, M Winget, B M Fendly, H M Shepard, A Ullrich, p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Molecular and Cellular Biology. ,vol. 9, pp. 1165- 1172 ,(1989) , 10.1128/MCB.9.3.1165
Shile Huang, Mary-Ann Bjornsti, Peter J. Houghton, Rapamycins: mechanism of action and cellular resistance. Cancer Biology & Therapy. ,vol. 2, pp. 222- 232 ,(2003) , 10.4161/CBT.2.3.360
P. Carter, L. Presta, C. M. Gorman, J. B. Ridgway, D. Henner, W. L. Wong, A. M. Rowland, C. Kotts, M. E. Carver, H. M. Shepard, Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 89, pp. 4285- 4289 ,(1992) , 10.1073/PNAS.89.10.4285
Dihua Yu, Tong Jing, Bolin Liu, Jun Yao, Ming Tan, Timothy J McDonnell, Mien-Chie Hung, Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase Molecular Cell. ,vol. 2, pp. 581- 591 ,(1998) , 10.1016/S1097-2765(00)80157-4
Kristine S. Klos, Xiaoyan Zhou, Sangkyou Lee, Lianglin Zhang, Wentao Yang, Yoichi Nagata, Dihua Yu, Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer. ,vol. 98, pp. 1377- 1385 ,(2003) , 10.1002/CNCR.11656
Yuhong Lu, Xiaolin Zi, Michael Pollak, Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells International Journal of Cancer. ,vol. 108, pp. 334- 341 ,(2004) , 10.1002/IJC.11445
Yotaro Izumi, Lei Xu, Emmanuelle di Tomaso, Dai Fukumura, Rakesh K. Jain, Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature. ,vol. 416, pp. 279- 280 ,(2002) , 10.1038/416279B
Yoichi Nagata, Keng-Hsueh Lan, Xiaoyan Zhou, Ming Tan, Francisco J. Esteva, Aysegul A. Sahin, Kristine S. Klos, Ping Li, Brett P. Monia, Nina T. Nguyen, Gabriel N. Hortobagyi, Mien-Chie Hung, Dihua Yu, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell. ,vol. 6, pp. 117- 127 ,(2004) , 10.1016/J.CCR.2004.06.022